Skip to content

Digital Lifestyle Intervention for Lung Cancer Survivors

Effect of a Digital Lifestyle Intervention on Health-Related Quality of Life in Non-Small Cell Lung Cancer Survivors (QUALUCA): a Multicenter Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05819346
Acronym
QUALUCA
Enrollment
88
Registered
2023-04-19
Start date
2023-08-01
Completion date
2026-01-31
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Keywords

Physical activity, Exercise, Nutrition, Breathing, Relaxation, Mobile application, Rehabilitation aftercare

Brief summary

The aim of this study is to assess the efficacy of a digital lifestyle intervention in non-small cell lung cancer (NSCLC) survivors on health-related quality of life (HRQoL) over three months.

Detailed description

Lung cancer survivors suffer from reduced physical and psychological functioning as well as decreased overall health-related quality of life (HRQoL) due to cancer symptoms, cancer treatments, and comorbidities. Experienced symptoms by lung cancer survivors, such as cancer-related fatigue or dyspnea, persist after active treatment ends. Therefore, lung cancer survivors should receive continuous attention regarding their health and HRQoL beyond the expected cancer cure. Physical activity, healthy nutrition, and breathing/relaxation exercises before, during, and after cancer treatments can increase physical as well as psychological functioning and HRQoL. Thus, the adhesion to an appropriate healthy lifestyle is crucial and represents an effective adjunctive strategy in the management of lung cancer survivors. Most lung cancer survivors, however, are sedentary and fail to meet official lifestyle recommendations, for instance, of the American Cancer Society or the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). The present project evaluates a mobile application for non-small cell lung cancer (NSCLC) survivors that will be used for three months after rehabilitation or treatment has finished. The main foci of the mobile application are physical activity, nutrition, and breathing/relaxation. The contents of the mobile application and the mobile application itself were developed in an iterative co-creation process involving software developers and potential users as well as researchers and clinicians from different disciplines (e.g., physical therapy and nutritional therapy).

Interventions

BEHAVIORALLifestyle

Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after rehabilitation or treatment has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.

Sponsors

Kai-Uwe Schmitt, PhD, MEng, ICID
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Diagnosis of non-small cell lung cancer (NSCLC) * Estimated life expectancy of ≥ six months (judged by local investigators/responsible health professionals) * Undergoing inpatient or outpatient rehabilitation OR completion of planned surgery, chemotherapy, or radiation therapy for NSCLC within the past 24 weeks * Knowledge of German to understand study material and assessments * Access to a cell phone or tablet * Written informed consent

Exclusion criteria

* Inability to provide informed consent * Inability to participate in the intervention because of physical, cognitive, or safety reasons (judged by local investigators/responsible health professionals)

Design outcomes

Primary

MeasureTime frameDescription
Health-related quality of life (Scale-Global health status)Change from baseline to 3 monthsEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) (2 items; 7-point Likert-type scale; the score ranges from 0 to 100; a high score for the global health status represents a high HRQoL)

Secondary

MeasureTime frameDescription
Functional exercise capacityChange from baseline to 3 months1-Minute Sit-to-Stand Test (number of repetitions)
Psychological distressChange from baseline to 3 monthsShort form of the Patient Health Questionnaire (PHQ-4) (4 items)
Cancer-related fatigueChange from baseline to 3 monthsBrief Fatigue Inventory (BFI) (9 items)
EnablementChange from baseline to 3 monthsShortened version of the Patient Enablement Scale-13 (PEN-13) (5 out of 13 items; 5-point Likert-type scale)
Self-rated healthWeekly for 3 monthsEuroQol Group Visual Analogue Scale (EQ VAS) (vertical visual analog scale that takes values between 100 \[best imaginable health\] and 0 \[worst imaginable health\], on which respondents provide a global assessment of their health)
Health-related quality of life (5 functional scales, 9 symptom scales/items)Change from baseline to 3 monthsEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) (28 items; 4-point Likert-type scale; 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 3 symptom scales (fatigue, nausea and vomiting, pain), 6 single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties); all scales and single-item measures range in score from 0 to 100)
Lung cancer-specific health-related quality of life (10 symptom scales/items)Change from baseline to 3 monthsEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 29 (lung cancer-specific module) (EORTC QLQ-LC29) (29 items; 4-point Likert-type scale / 5 multi-item scales and 5 single items; all scales and single-item measures range in score from 0 to 100)
Body mass index [kg/m²]Change from baseline to 3 monthsComputed using self-reported body weight \[kg\] and height \[m\]
Physical activity (self-reported)Change from baseline to 3 monthsModified Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) (physical activity before rehabilitation/treatment and physical activity over the last week)
Risk for low protein intakeChange from baseline to 3 monthsProtein Screener 55+ (Pro55+) (10 items)
AppetiteChange from baseline to 3 monthsSimplified Nutritional Appetite Questionnaire (SNAQ) (4 items; 5-point Likert-type scale)

Other

MeasureTime frameDescription
Experiences and satisfaction with the digital lifestyle intervention (intervention group only)At 3 months follow-up (end of the intervention)Short semi-structured interview; outcomes will be qualitatively assessed (no scale is used)
Treatments/support since baselineAt 3 months follow-up (end of the intervention)Cancer treatments (e.g., chemotherapy) and therapies/support (e.g., physical therapy, self-help group) participants might have received during the last 3 months (2 items)
Usability (intervention group only)At 3 months follow-up (end of the intervention)mHealth App Usability Questionnaire (MAUQ)
Acceptability, appropriateness, and feasibility (intervention group only)At 3 months follow-up (end of the intervention)Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) (4-item measures of implementation outcomes)

Countries

Switzerland

Contacts

Primary ContactAnja Frei, PhD
anja.frei@uzh.ch+41 44 634 43 60

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026